The drug, initially intended for use by diabetics, has soared in popularity as a result of the weight-loss effects.

Scholar Rock is also working on a treatment that helps preserve lean muscle that is often lost during rapid weight loss by patients taking the new class of GLP-1 drugs. Scholar Rock's stock is down 45 ...

Scholar Rock said on Monday its experimental drug apitegromab met the main goal of a late-stage trial in patients with a type of rare genetic disease, sending the company's shares surging in premarket ...

It feels as though just about every celebrity in Hollywood is using Ozempic - but what effect does the controversial drug ...

In phase 2, VK2735 reduced patients' weight by about 15% after 13 weeks of treatment and maintained a clean safety profile.

After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo ...

"It's very, very clear that physician spending is not the problem in healthcare." -- Jen Brull, MD, president of the American ...

Over the summer, we took a deep dive into “Ozempic Face,” a phenomenon that occurs when quick, significant weight loss leads ...

Today, DexCom is the leading CGM company, with an estimated 40% market share. Importantly, CGM products are relatively nascent. DexCom generates nearly $4 billion in annual sales on a user base of ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with the risk for retained gastric contents and ...

The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...